Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
+1.41 (0.25%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 559.25 - 566.52
52 week 383.87 - 605.93
Open 564.08
Vol / Avg. 466,682.00/770,069.00
Mkt cap 58.60B
P/E 109.70
Div/yield     -
EPS 5.13
Shares 102.15M
Beta 0.94
Inst. own 73%
Feb 8, 2016
Q4 2015 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 10, 2015
Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 4, 2015
Q3 2015 Regeneron Pharmaceuticals Inc Earnings Release
Nov 4, 2015
Q3 2015 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
Sep 17, 2015
Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Global Healthcare Conference
Sep 16, 2015
Regeneron Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 9, 2015
Regeneron Pharmaceuticals Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 18.50% 12.34%
Operating margin 34.50% 28.55%
EBITD margin - 31.60%
Return on average assets 17.38% 10.25%
Return on average equity 25.44% 15.46%
Employees 2,925 -
CDP Score - -


777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Company's marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 85
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 58
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 42
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 44
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 58
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 55
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 55
Bio & Compensation  - Reuters